Your session is about to expire
← Back to Search
Zanubrutinib for Lymphoma
Study Summary
This trial will evaluate the safety of zanubrutinib in cancer patients who have become intolerant to prior ibrutinib and/or acalabrutinib treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 41 Patients • NCT03145064Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I need more than 10 mg of prednisone or similar medication daily.My condition requires treatment before starting ibrutinib or acalabrutinib.My condition worsened while on ibrutinib or acalabrutinib treatment.I have serious heart issues, including recent heart attacks or unstable angina.My blood tests show enough neutrophils and platelets for treatment.I haven't had cancer treatment except immunotherapy in the last 7 days or immunotherapy in the last 4 weeks.I have had bleeding in my brain.I can take care of myself and am up and about more than half of my waking hours.I had severe side effects from Ibrutinib or Acalabrutinib that required stopping the treatment.You have a history of specific types of heart block without a pacemaker.
- Group 1: Zanubrutinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are currently partaking in this clinical experiment?
"This clinical trial necessitates 90 patients, who all comply with the established inclusion criteria. Patients have their pick of multiple locations to partake in this experiment, including Abington Hematology Oncology Associates in Drexel Hill, Pennsylvania and SSM Health Cancer Care- Dean M in Madison, Wisconsin."
What other research findings have been ascertained regarding Zanubrutinib?
"Presently, 37 clinical trials are testing the effectiveness of Zanubrutinib with 8 in their final phase. Guangzhou, Guangdong is at the epicenter of this research; however, there are 1104 sites carrying out these studies worldwide."
What medical conditions commonly respond to Zanubrutinib treatment?
"Zanubrutinib is typically utilised to treat waldenstrom macroglobulinemia, yet it has also proved effective for relapsed marginal zone lymphoma, lymphoma and one prior therapy."
Is this a pioneering clinical trial in its field?
"Zanubrutinib's journey began in 2016 with an exploratory Phase 1 trial conducted by MEI Pharma, Inc. and comprising 177 patients. Subsequently it was approved for further clinical trials which currently involve 37 studies being held across 324 cities spanning 32 countries worldwide."
Is this research effort currently seeking new participants?
"In accordance with clinicaltrials.gov, this research endeavor is actively searching for volunteers to participate in the study which was initially advertised on October 15th 2019 and revised as recently as September 6th 2022."
Are there any known risks associated with using Zanubrutinib for patients?
"Based on the available evidence, Zanubrutinib was assessed a score of 2; while there is some data to suggest its safety, no studies have yet been conducted to support efficacy."
Are there any geographic limitations on the current implementation of this experiment?
"This clinical trial is taking place at 38 different medical sites, including Drexel Hill, Madison and Green Bay. Therefore it is recommended that interested parties select the closest centre to them in order to reduce travel demands associated with participation."
Share this study with friends
Copy Link
Messenger